{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:51Z","timestamp":1793214651801,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ophtha.2018.06.015","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T11:26:07Z","timestamp":1532690767000},"page":"1984-1993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis"],"prefix":"10.1016","volume":"125","author":[{"given":"Quan Dong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2085-3548","authenticated-orcid":false,"given":"Pauline T.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir J.","family":"Sepah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alay","family":"Banker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Chernock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Mudumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.06.015_bib1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/postgradmedj-2017-134891","article-title":"Uveitis: a sight-threatening disease which can impact all systems","volume":"93","author":"Krishna","year":"2017","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ophtha.2018.06.015_bib2","first-page":"478","article-title":"Impact of uveitis on quality of life: a prospective study from a tertiary referral rheumatology-ophthalmology collaborative uveitis center in Italy","volume":"19","author":"Fabiani","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ophtha.2018.06.015_bib3","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/aos.12987","article-title":"Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis","volume":"94","author":"Thorne","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1869-5760-3-64","article-title":"Healthcare costs and\u00a0utilization for privately insured patients treated for non-infectious uveitis in the USA","volume":"3","author":"Chu","year":"2013","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ophtha.2018.06.015_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","article-title":"Understanding uveitis: the impact of research on visual outcomes","volume":"30","author":"de Smet","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2018.06.015_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/09273948.2014.968671","article-title":"The Manchester Uveitis Clinic: the first 3000 patients, 2\u2014uveitis manifestations, complications, medical and surgical management","volume":"23","author":"Jones","year":"2015","journal-title":"Ocular Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.06.015_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00281-014-0433-9","article-title":"Autoimmune and autoinflammatory mechanisms in uveitis","volume":"36","author":"Lee","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2011.11.004","article-title":"Interplay between innate and adaptive immunity in the development of non-infectious uveitis","volume":"31","author":"Willermain","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2018.06.015_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-017-0915-5","article-title":"MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis","volume":"14","author":"Lipski","year":"2017","journal-title":"J\u00a0Neuroinflamm"},{"key":"10.1016\/j.ophtha.2018.06.015_bib11","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1172\/JCI42440","article-title":"A\u00a0look at autoimmunity and inflammation in the eye","volume":"120","author":"Caspi","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2018.06.015_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.iae.0000250601.15893.5f","article-title":"Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion","author":"Nguyen","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2018.06.015_bib13","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/OPTH.S89341","article-title":"Management of noninfectious posterior uveitis with intravitreal drug therapy","volume":"10","author":"Tan","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib14","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3109\/09273948.2013.855799","article-title":"The Manchester Uveitis Clinic: the first 3000 patients\u2014epidemiology and casemix","volume":"23","author":"Jones","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.06.015_bib15","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"8","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"key":"10.1016\/j.ophtha.2018.06.015_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A\u00a0practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/09273948.2015.1114778","article-title":"Sustained-release corticosteroids for uveitis","volume":"23","author":"Cunningham","year":"2015","journal-title":"Ocular Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2018.06.015_bib19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2018.06.015_bib20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive NIU controlled by corticosteroids: a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2018.06.015_bib21","first-page":"1075","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology","volume":"125","author":"Suhler","year":"2018"},{"issue":"Suppl 3","key":"10.1016\/j.ophtha.2018.06.015_bib23","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ophtha.2018.06.015_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00007691-200110000-00012","article-title":"From beach to bedside: history of the development of sirolimus","volume":"23","author":"Napoli","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ophtha.2018.06.015_bib25","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.91.26.12574","article-title":"RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12\/rapamycin complex","volume":"91","author":"Chiu","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2018.06.015_bib26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ophtha.2018.06.015_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.aaa3870","article-title":"Architecture of human mTOR complex 1","volume":"351","author":"Aylett","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2018.06.015_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signaling in T cell fate decision","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ni.2005","article-title":"The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2","volume":"12","author":"Delgoffe","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib33","series-title":"Rapamune (package insert)","year":"2015"},{"key":"10.1016\/j.ophtha.2018.06.015_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/02713689308999487","article-title":"Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction","volume":"12","author":"Roberge","year":"1993","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2018.06.015_bib35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/bjo.2004.048199","article-title":"The efficacy of sirolimus in the treatment of patients with refractory uveitis","volume":"89","author":"Shanmuganathan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2885.2008.00986.x","article-title":"Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses","volume":"31","author":"Douglas","year":"2008","journal-title":"J\u00a0Vet Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.06.015_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1590\/S0004-27492009000100004","article-title":"Testing intravitreal toxicity of rapamycin in rabbit eyes","volume":"72","author":"Manzano","year":"2009","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/jop.2011.0226","article-title":"Tolerability and pharmacokinetics of intravitreal sirolimus","volume":"28","author":"Mudumba","year":"2012","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2018.06.015_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ophtha.2011.07.034","article-title":"A\u00a0randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema","volume":"119","author":"Dugel","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.06.015_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1869-5760-3-32","article-title":"Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE study","volume":"3","author":"Nguyen","year":"2013","journal-title":"J\u00a0Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ophtha.2018.06.015_bib41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.4.2.4","article-title":"One-year outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis","volume":"4","author":"Ibrahim","year":"2015","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib42","first-page":"T3","article-title":"The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis. An American Ophthalmological Society Thesis","volume":"114","author":"Nguyen","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2018.06.015_bib43","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: a phase III sirolimus study assessing double-masked uveitis treatment","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.06.015_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.06.015_bib45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","volume":"137","author":"del Amo","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2018.06.015_bib47","author":"Wilson"},{"key":"10.1016\/j.ophtha.2018.06.015_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-5173(00)00617-7","article-title":"Solubilization of rapamycin","volume":"213","author":"Simamora","year":"2001","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ophtha.2018.06.015_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: a review of the evidence","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ophtha.2018.06.015_bib50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ajo.2010.05.036","article-title":"Scale for photographic grading of vitreous haze in uveitis","volume":"150","author":"Davis","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib51","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ophtha.2014.07.007","article-title":"Long-term clinical outcome and causes of vision loss in patients with uveitis","volume":"121","author":"Tomkins-Netzer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.06.015_bib52","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1167\/iovs.17-22049","article-title":"Association between visual function response and reduction of inflammation in noninfectious uveitis of the posterior segment","volume":"58","author":"Lescrauwaet","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2018.06.015_bib53","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.ajo.2014.09.003","article-title":"Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency","volume":"158","author":"Zarranz-Ventura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib54","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment Trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.06.015_bib55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.06.015_bib56","doi-asserted-by":"crossref","first-page":"37676","DOI":"10.1038\/srep37676","article-title":"Intravitreal infusion: a novel approach for intraocular drug delivery","volume":"6","author":"Tian","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2018.06.015_bib57","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Intravitreal injection technique and monitoring: updated guidelines of an expert panel","volume":"34","author":"Avery","year":"2014","journal-title":"Retina"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017335388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017335388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:06:38Z","timestamp":1758981998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017335388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0161642017335388"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.06.015","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}